---
format:
  revealjs:
    spotlight: true
    touch: true
    controls: true
    pointer: true
    center-title-slide: false
    transition: fade
    transition-speed: fast
    scrollable: true
    slide-number: true
    incremental: false
    multiplex: true
    chalkboard: true
    theme: [default, custom.scss]
    filters:
     - highlight-text
bibliography: references.bib
lightbox: true
csl: diagnostic-microbiology-and-infectious-disease.csl
---

## Lecture 5: β-lactams, Part 2: <br> Cephalosporins and carbapenems {background-image="images/Bronzu.png" background-opacity="0.1"}

<br> <br> <br> <br>

**Russell E. Lewis** <br> Associate Professor of Infectious Diseases <br> Department of Molecular Medicine <br> University of Padua

<br> {{< fa solid envelope size=1x >}} russelledward.lewis\@unipd.it <br> {{< fa brands github size=1x >}} [https://github.com/Russlewisbo](https://github.com/Russlewisbo/ESCMID_2022_talk)

![](images/University_of_Padua_seal.svg){width="100"}

## Agenda

## Discovery of cephalosporins {.smaller}

<br>

::::: columns
::: {.column width="40%"}
![](images/Bronzu.png){width="800"}
:::

::: {.column width="60%"}
<br>

-   Bronzu performed epidemiological studies of typhoid infection in Cagliari, noted *Salmonella typhi* was not cultured once sewer water was discharged into the sea
-   Isolated the mold *Cephalosporium* (now known as *Acremonium*) in 1948 from seawater
-   Noticed that these cultures produced substances (he named mycetin) that were effective against *Salmonella typhi*, the cause of typhoid fever, which had beta-lactamase.
-   After he failed to find support from Italian government, he sent the fungus to Howard Florey at Oxford
-   1962: Isolation of cephalosporin C
:::
:::::

## Mechanism of action of cephalosporins: <br> Same as β-lactams

<br>

::::: columns
::: {.column width="50%"}
![Inhibition of transpeptidase (PBP)](https://i.makeagif.com/media/4-07-2017/l7_PRO.gif)
:::

::: {.column width="50%"}
![Lysis of growing bacterial cells](https://i.makeagif.com/media/10-05-2017/e3c7kf.gif)
:::
:::::

<br>

## First generation cephalosporins; <br> derivatives of 7-ACA {.smaller}

![](images/1gen.png){fig-align="center" width="400"}

::: aside
-   Gram positive activity: Cover Methicillin-sensitive *S. aureus* (MSSA) and streptococci:
-   Used for uncomplicated skin and soft-tissue infections (SSI)
-   Surgical prophylaxis: cefazolin
-   Some Gram negative coverage in urine: *P. mirabilis, E. coli, and K. pneumoniae*
:::

## Pharmacokinetics: 1st generation cephalosporins {.smaller}

<br> <br>

+-------------------+-------------------------------------------------------------------+
| **Absorption**    | Cefadroxil (90%); cephalexin (90%); cefazolin (IV only)           |
+-------------------+-------------------------------------------------------------------+
| **Distribution**  | -   0.19-0.35 L/kg                                                |
|                   |                                                                   |
|                   | -   Protein binding: 20% cefadroxil, cephalexin; 73-87% cefazolin |
|                   |                                                                   |
|                   | -   25% bile:serum; cefazolin:29-300%                             |
|                   |                                                                   |
|                   | -   5-10% CSF:blood (possibly for cefazolin with higher doses)    |
+-------------------+-------------------------------------------------------------------+
| **Metabolism**    | -   No metabolism                                                 |
|                   |                                                                   |
|                   | -   t½: Cefazolin (2 hrs); cefadroxil (1.5 hrs); cephalexin (1hr) |
+-------------------+-------------------------------------------------------------------+
| **Elimination**   | Renal 100%, impaired by probenicid                                |
+-------------------+-------------------------------------------------------------------+
| **PK:PD target**  | ≥ 40-50% *f*Time~\>MIC~                                           |
+-------------------+-------------------------------------------------------------------+
| **Typical doses** | Cefazolin: 1-2 gram IV every 8 hours                              |
|                   |                                                                   |
|                   | Cefadroxil: 500-1000 mg BID                                       |
|                   |                                                                   |
|                   | Cephalexin 250-1000 mg QID                                        |
+-------------------+-------------------------------------------------------------------+

::: aside
Source: Sanford Guide
:::

## Avoid cefazolin for CNS infections?

<br>

::::: columns
::: {.column width="50%"}
![](images/myth1.png)
:::

::: {.column width="50%"}
![](images/myth2.png)
:::
:::::

::: aside
[@mccreary.etal_2023b]
:::

## Why this myth has been busted?

<br>

-   **Earlier recommendations based on breakthrough reports with cephalothin and single point samples suggesting low CSF concentrations**
-   **More recent data have documented attainment of therapeutic exposures with higher dose regimens:**
    -   A recent narrative review on the treatment of cefazolin for CNS infections (including 11 reports describing cefazolin treatment of spinal epidural abscesses in a total of 104 patients) recommends [2 g IV every 6 hours or a continuous infusion of 8–10 g daily]{bg-color="#ffe536"} instead of the traditional 1–2 g IV every 8 hours dosing scheme to optimize pharmacokinetic/pharmacodynamic properties

::: aside
[@antosz.etal_2023a]
:::

## Another cefazolin myth busted? <br> penicillin cross-allergy {.smaller}

<br>

::::: columns
::: {.column width="50%"}
![](images/myth3.png){width="500"}
:::

::: {.column width="50%"}
![](images/myth4.png){width="600"}
:::
:::::

::: aside
[@mccreary.etal_2023b]
:::

## Second generation cephalosporins {.smaller}

![](images/2ndgen.png){fig-align="center"}

## Spectrum of activity {.smaller}

<br>

![](images/spectrum.png){fig-align="center"}

::: aside
Source. Sanford's Guide
:::

## Pharmacokinetics: <br> {.smaller}

## Representative 2nd generation cephalosporins {.smaller}

<br> <br>

+-------------------+------------------------------------------------------------------------+
| **Absorption**    | Cefuroxime (52%), cefprozil (95%), cefaclor (93%)                      |
+-------------------+------------------------------------------------------------------------+
| **Distribution**  | -   0.15-0.35 L/kg                                                     |
|                   |                                                                        |
|                   | -   Protein binding: 36-50%                                            |
|                   |                                                                        |
|                   | -   25% bile:serum; cefazolin:29-300%                                  |
|                   |                                                                        |
|                   | -   5-10% CSF:blood (possibly for cefazolin with higher doses)         |
+-------------------+------------------------------------------------------------------------+
| **Metabolism**    | -   No metabolism                                                      |
|                   |                                                                        |
|                   | -   t½: Ccefuroxime (1.5hrs); cefadroxil (1.5 hrs); cefotetan( 3-4 hr) |
+-------------------+------------------------------------------------------------------------+
| **Elimination**   | Renal 100%                                                             |
+-------------------+------------------------------------------------------------------------+
| **PK:PD target**  | ≥ 40-50% *f*Time~\>MIC~                                                |
+-------------------+------------------------------------------------------------------------+
| **Typical doses** | cefaclor: 250-500 mg TID                                               |
|                   |                                                                        |
|                   | cefuroxime: 250-500 BID                                                |
|                   |                                                                        |
|                   | cefotetan: 1-2 gram IV q12h                                            |
+-------------------+------------------------------------------------------------------------+

::: aside
Source: Sanford Guide
:::

## 2nd generation cephalosporins: <br> What is their role? {.smaller}

-   Cefotetan- GI surgical prophylaxis (resistance is increasing in *B. fragilis*)

-   Upper respiratory tract infections, CAP, gonorrhea,...but these are "in between" antibiotics and often passed over for better options

## 3rd generation cephalosporins {.smaller}

<br>

![](images/3rdgen.png){fig-align="center" width="400"}

## 3rd generation cephalosporins <br> spectrum of activity <br> <br>

![](images/3rdgenspectrum.png){fig-align="center"}

## References

<br>

<br>
